67 related articles for article (PubMed ID: 24286313)
1. Establishment and characterization of bortezomib-resistant U266 cell line: constitutive activation of NF-κB-mediated cell signals and/or alterations of ubiquitylation-related genes reduce bortezomib-induced apoptosis.
Park J; Bae EK; Lee C; Choi JH; Jung WJ; Ahn KS; Yoon SS
BMB Rep; 2014 May; 47(5):274-9. PubMed ID: 24286313
[TBL] [Abstract][Full Text] [Related]
2. Silencing of SENP2 in Multiple Myeloma Induces Bortezomib Resistance by Activating NF-κB Through the Modulation of IκBα Sumoylation.
Xie H; Gu Y; Wang W; Wang X; Ye X; Xin C; Lu M; Reddy BA; Shu P
Sci Rep; 2020 Jan; 10(1):766. PubMed ID: 31964975
[TBL] [Abstract][Full Text] [Related]
3. Hyaluronan and proteoglycan link protein 1 (HAPLN1) activates bortezomib-resistant NF-κB activity and increases drug resistance in multiple myeloma.
Huynh M; Pak C; Markovina S; Callander NS; Chng KS; Wuerzberger-Davis SM; Bakshi DD; Kink JA; Hematti P; Hope C; Asimakopoulos F; Rui L; Miyamoto S
J Biol Chem; 2018 Feb; 293(7):2452-2465. PubMed ID: 29279332
[TBL] [Abstract][Full Text] [Related]
4. 5-Aza-2'-Deoxycytidine Alters the Methylation Profile of Bortezomib-Resistant U266 Multiple Myeloma Cells and Affects Their Proliferative Potential.
Łuczkowska K; Kulig P; Rusińska K; Baumert B; Machaliński B
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069103
[TBL] [Abstract][Full Text] [Related]
5. The STAT3 inhibitor stattic overcome bortezomib-resistance in multiple myeloma via decreasing PSMB6.
Yuan C; Yuan M; Li W; Cheng H; Luo J; Zhang Q; Shi M; Niu M; Yang J; Sun Z; Yan Z; Xu K; Li Z; Yao Y
Exp Cell Res; 2023 Aug; 429(1):113634. PubMed ID: 37207970
[TBL] [Abstract][Full Text] [Related]
6. Phenotypic, genomic and functional characterization reveals no differences between CD138++ and CD138low subpopulations in multiple myeloma cell lines.
Paíno T; Sarasquete ME; Paiva B; Krzeminski P; San-Segundo L; Corchete LA; Redondo A; Garayoa M; García-Sanz R; Gutiérrez NC; Ocio EM; San-Miguel JF
PLoS One; 2014; 9(3):e92378. PubMed ID: 24658332
[TBL] [Abstract][Full Text] [Related]
7. [Mechanism and Clinical Significance of
Wang YR; Ma YP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):138-145. PubMed ID: 38387912
[TBL] [Abstract][Full Text] [Related]
8. Clinical proof of concept for a safe and effective NF-κB-targeting strategy in multiple myeloma.
Tornatore L; Capece D; D'Andrea D; Begalli F; Verzella D; Bennett J; Acton G; Campbell EA; Kelly J; Tarbit M; Adams N; Bannoo S; Leonardi A; Sandomenico A; Raimondo D; Ruvo M; Chambery A; Oblak M; Al-Obaidi MJ; Kaczmarski RS; Gabriel I; Oakervee HE; Kaiser MF; Wechalekar A; Benjamin R; Apperley JF; Auner HW; Franzoso G
Br J Haematol; 2019 May; 185(3):588-592. PubMed ID: 30255568
[No Abstract] [Full Text] [Related]
9.
Smith-Norowitz TA; Norowitz EM; Abdelmajid H; Kohlhoff S
Ann Clin Lab Sci; 2024 Mar; 54(2):262-264. PubMed ID: 38802146
[No Abstract] [Full Text] [Related]
10. Phenotypic and functional characterization of a bortezomib-resistant multiple myeloma cell line by flow and mass cytometry.
Baughn LB; Sachs Z; Noble-Orcutt KE; Mitra A; Van Ness BG; Linden MA
Leuk Lymphoma; 2017 Aug; 58(8):1931-1940. PubMed ID: 27981867
[TBL] [Abstract][Full Text] [Related]
11. Established immunoglobulin producing myeloma (IgE) and lymphoblastoid (IgG) cell lines from an IgE myeloma patient.
Nilsson K; Bennich H; Johansson SG; Pontén J
Clin Exp Immunol; 1970 Oct; 7(4):477-89. PubMed ID: 4097745
[TBL] [Abstract][Full Text] [Related]
12. Distribution of plasma cell markers and intracellular IgE in cell line U266.
Lagging E; van Hage-Hamsten M; Härfast B; Halldén G
Immunol Lett; 1996 Jan; 49(1-2):71-7. PubMed ID: 8964613
[TBL] [Abstract][Full Text] [Related]
13. Characterization of the Newly Established Homoharringtonine- (HHT-) Resistant Cell Lines and Mechanisms of Resistance.
Li F; Ling Q; Hu C; Wang H; Ye W; Li X; Zhang X; Lin X; Wei W; Huang X; Qian Y; Zhuang H; Jin J; Lu Y
J Oncol; 2022; 2022():2813938. PubMed ID: 36081671
[TBL] [Abstract][Full Text] [Related]
14. Timelapse viability assay to detect division and death of primary multiple myeloma cells in response to drug treatments with single cell resolution.
Mark C; Callander NS; Chng K; Miyamoto S; Warrick J
Integr Biol (Camb); 2022 Jun; 14(3):49-61. PubMed ID: 35653717
[TBL] [Abstract][Full Text] [Related]
15. E3 Ubiquitin Ligase in Anticancer Drugdsla Resistance: Recent Advances and Future Potential.
Liu Y; Duan C; Zhang C
Front Pharmacol; 2021; 12():645864. PubMed ID: 33935743
[TBL] [Abstract][Full Text] [Related]
16. HDAC6-Selective Inhibitor Overcomes Bortezomib Resistance in Multiple Myeloma.
Lee SW; Yeon SK; Kim GW; Lee DH; Jeon YH; Yoo J; Kim SY; Kwon SH
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33572814
[TBL] [Abstract][Full Text] [Related]
17. Aloe-Emodin Induces Endoplasmic Reticulum Stress-Dependent Apoptosis in Colorectal Cancer Cells.
Cheng C; Dong W
Med Sci Monit; 2018 Sep; 24():6331-6339. PubMed ID: 30199885
[TBL] [Abstract][Full Text] [Related]
18. Proteasome and heat shock protein 70 (HSP70) inhibitors as therapeutic alternative in multiple myeloma.
Eugênio AIP; Fook-Alves VL; de Oliveira MB; Fernando RC; Zanatta DB; Strauss BE; Silva MRR; Porcionatto MA; Colleoni GWB
Oncotarget; 2017 Dec; 8(70):114698-114709. PubMed ID: 29383113
[TBL] [Abstract][Full Text] [Related]
19. MTI-101 treatment inducing activation of Stim1 and TRPC1 expression is a determinant of response in multiple myeloma.
Emmons MF; Anreddy N; Cuevas J; Steinberger K; Yang S; McLaughlin M; Silva A; Hazlehurst LA
Sci Rep; 2017 Jun; 7(1):2685. PubMed ID: 28578393
[TBL] [Abstract][Full Text] [Related]
20. Gambogenic acid inhibits LPS-simulated inflammatory response by suppressing NF-κB and MAPK in macrophages.
Yu X; Zhao Q; Zhang H; Fan C; Zhang X; Xie Q; Xu C; Liu Y; Wu X; Han Q; Zhang H
Acta Biochim Biophys Sin (Shanghai); 2016 May; 48(5):454-61. PubMed ID: 27025602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
